- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
- Biohaven Announces Proposed Public Offering of Common Shares
- Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
- Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
More ▼
Key statistics
On Thursday, Biohaven Ltd (BHVN:NYQ) closed at 38.54, -38.05% below its 52-week high of 62.21, set on Mar 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 38.95 |
---|---|
High | 38.95 |
Low | 36.77 |
Bid | 17.00 |
Offer | 39.89 |
Previous close | 38.54 |
Average volume | 2.03m |
---|---|
Shares outstanding | 88.26m |
Free float | 72.29m |
P/E (TTM) | -- |
Market cap | 3.40bn USD |
EPS (TTM) | -5.67 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 00:00 BST.
More ▼